 PRINCETON, N.J., Nov. 27, 2020 GLOBE NEWSWIRE -- Advaxis, Inc. Nasdaq: ADXS the Company, a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced the closing of an underwritten public offering of 26,666,666 shares of common stock and warrants to purchase up to 13,333,333 shares of common stock, along with an additional 3,999,999 shares of common stock and 1,999,999 warrants pursuant to the full exercise of the underwriters option. The shares of common stock and warrants were sold together at a combined public offering price of 0.30 per share for total gross proceeds of approximately 9.2 million, before underwriting commissions and estimated expenses. 